The safety of sodium glucose transporter 2 inhibitors and trends in clinical and hemodynamic parameters in patients with left ventricular assist devices.

Alexander FardmanAfek KodeshAllison Joyce SiegelAmitai SegevEhud RegevElad MaorAnat BerkovitchRafael KupersteinAvi MorganEyal NahumYael PeledAvishay Grupper

Published in: Artificial organs (2024)

SGLT2-I treatment is safe in LVAD patients and might contribute to reduction in patients sPAP.

Keyphrases

end stage renal disease
ejection fraction
left ventricular
newly diagnosed
heart failure
prognostic factors
coronary artery disease
aortic stenosis
transcatheter aortic valve replacement